Physician

Daniel H Rosler, M.D.

According to 2025 Medicare claims, Daniel Rosler, M.D. (NPI: 1134124159) practices rheumatology in the Milwaukee-Waukesha, WI market, with the plurality of this provider's patient population coming from Milwaukee, WI. This provider's primary affiliated billing organization is MILWAUKEE RHEUMATOLOGY CENTER, SC (NPI: 1306890470; TIN: 392008962) and primary practice location at 53215-3660. Rosler is affiliated with the Mercy Health Corporation (ACO ID: A2097), participating under the MSSP model.

Rosler's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 209 traditional Medicare patients, billed 98,467 HCPCS/CPT codes, and received $1,200,555 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,834 prescription claims across 334 beneficiaries totaling $3,685,713 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 1 records totaling $125. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $1,465,775 to $1,200,555. In contrast, Part D prescription costs have risen steadily, from $2,296,844 to $3,685,713. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	429	85,068	$1,465,775
2016	420	91,546	$1,736,995
2017	400	100,257	$1,901,994
2018	357	97,426	$1,953,199
2019	329	101,041	$1,793,137
2020	281	103,473	$1,677,937
2021	288	95,975	$1,417,294
2022	237	105,507	$1,267,819
2023	237	103,350	$1,264,108
2024	209	98,467	$1,200,555

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	475	4,839	$2,296,844
2016	447	4,491	$2,493,734
2017	426	4,303	$2,864,179
2018	399	3,954	$2,935,042
2019	373	3,473	$3,225,819
2020	349	3,257	$3,380,653
2021	350	3,029	$3,524,943
2022	340	3,129	$3,826,943
2023	332	3,027	$3,571,446
2024	334	2,834	$3,685,713

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	52	331	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	144	241	$83
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	93	124	$56
96415	Administration of chemotherapy into vein, each additional hour	24	141	$21
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	69	89	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	107	3,080	$770,070
Xeljanz Xr	Tofacitinib Citrate	74	2,340	$457,510
Enbrel Sureclick	Etanercept	40	1,120	$317,412
Cimzia (2 Pack)	Certolizumab Pegol	53	1,485	$314,484
Humira(Cf)	Adalimumab	19	812	$203,117

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$125	UCB, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel H. Rosler, M.D.?

Tedicare shows public-source Medicare data for Daniel H. Rosler, M.D. (NPI 1134124159), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel H. Rosler, M.D. have ACO affiliation data?

Daniel H. Rosler, M.D. is shown with ACO affiliation data for Mercy Health Corporation (MSSP, ACO ID A2097).

What billing organization is linked to Daniel H. Rosler, M.D.?

Daniel H. Rosler, M.D. is linked to MILWAUKEE RHEUMATOLOGY CENTER, SC (billing NPI 1306890470) in the available physician profile data.

Does Daniel H. Rosler, M.D. have Open Payments data?

Daniel H. Rosler, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.